MYOMO INC. NEW DL-,0001

Myomo, Inc.(NYSEAM:MYO) added to Russell 3000 Growth Index» Mehr auf marketscreener.com

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, will host an Investor & Analyst Day event today from 10 a.m. to 3 p.m. Eastern time during which management will provide an in-depth review of the Company's business model, provide a tour of its new headquarters and manufacturing facility and discuss l.» Mehr auf businesswire.com

Squarepoint Ops LLC purchased a new position in shares of Myomo, Inc. (NYSEAMERICAN:MYO – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 11,499 shares of the company’s stock, valued at approximately $74,000. A number of other large investors have also added to or reduced their stakes in MYO. AIGH Capital Management LLC grew its position in Myomo by 21.7% during the fourth quarter. AIGH Capital Management LLC now owns 3,381,567 shares of the company’s stock worth $21,777,000 after buying an additional 602,719 shares in the last quarter. Portolan Capital Management LLC bought a new stake in Myomo during the fourth quarter worth $2,446,000. Manatuck Hill Partners LLC bought a new stake in Myomo during the fourth quarter worth $1,582,000. Aristides Capital LLC bought a new stake in Myomo during the fourth quarter worth $1,288,000. Finally, Thompson Siegel & Walmsley LLC bought a new stake in Myomo during the fourth quarter worth $1,288,000. Institutional investors and hedge funds own 44.99% of the company’s stock. Myomo Stock Down 3.0% Shares of MYO opened at $2.88 on Wednesday. Myomo, Inc. has a 52 week low of $2.76 and a 52 week high of $7.17. The company has a market cap of $87.12 million, a PE ratio of -12.52 and a beta of 1.68. The firm has a fifty day moving average price of $3.88. Insider Activity In related news, CEO Paul R. Gudonis bought 30,000 shares of the stock in a transaction that occurred on Thursday, May 15th. The stock was acquired at an average cost of $3.22 per share, with a total value of $96,600.00. Following the transaction, the chief executive officer now directly owns 1,051,671 shares in the company, valued at approximately $3,386,380.62. This trade represents a 2.94% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Thomas F. Kirk purchased 7,400 shares of the firm’s stock in a transaction on Thursday, March 13th. The shares were acquired at an average price of $5.00 per share, with a total value of $37,000.00. Following the completion of the acquisition, the director now owns 255,933 shares in the company, valued at approximately $1,279,665. This trade represents a 2.98% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 126,167 shares of company stock worth $427,093. Insiders own 4.54% of the company’s stock. Analyst Upgrades and Downgrades Several research firms have weighed in on MYO. Alliance Global Partners restated a “buy” rating on shares of Myomo in a research note on Tuesday, March 11th. HC Wainwright upped their target price on Myomo from $7.50 to $9.50 and gave the stock a “buy” rating in a research note on Wednesday, March 12th. Craig Hallum cut their target price on Myomo from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Thursday, May 8th. Finally, Ascendiant Capital Markets upped their target price on Myomo from $11.00 to $11.50 and gave the stock a “buy” rating in a research note on Thursday, June 5th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $9.63. Get Our Latest Analysis on MYO About Myomo (Free Report) Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living.» Mehr auf defenseworld.net